Evaluation of supplemental administration of eviprostat in patients with benign prostatic hyperplasia with persistent symptoms following treatment with α1-adrenoceptor blocker

Acta Urologica Japonica

Volumn 54, Issue 5, 2008, Pages 341-344

  Naruoka, Takehito ^a   Suzuki, Yasuyuki ^b   Furuta, Akira ^b   Endo, Katsuhisa ^a   Sugaya, Shingo ^c   Egawa, Shin ^b  

^a JR Tokyo General Hospital

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Department of Urology

Author keywords

BPH; Eviprostat

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ANTIINFLAMMATORY AGENT; ETAMSYLATE; EVIPROSTAT; NAFTOPIDIL; NAPHTHALENE DERIVATIVE; PIPERAZINE DERIVATIVE; PLANT EXTRACT;

AGED; ARTICLE; DRUG ANTAGONISM; DRUG COMBINATION; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; QUALITY OF LIFE;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; DRUG COMBINATIONS; ETHAMSYLATE; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PIPERAZINES; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 46049118779     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Japanese source
2. Taoka R, Tsukuda F, Ishikawa M, et al.: Association of prostatic inflammation with downregulation of macrophage inhibitory cytokine-1 gene in symptomatic benign prostatic hyperplasia. J Urol 171: 2330-2335, 2004
3. Oka M, Tachibana M, Noda K, et al.: Relevance of anti-reactive oxygen species activity to antiinflammatory activity of components of Eviprostat®, a phytotherapeutic agent for benign prostatic hyperplasia. Phytomedicine 14: 465-472, 2007
4. Japanese source
5. Japanese source
6. Lee JY, Kim HW, Lee SJ, et al.: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94: 817-820, 2004
7. McConnell JD, Roehrborn CG, Bautista OM, et al.: The long term effect of doxazosin, finasteride, and combination therapy on the clinical progression of BPH. N Eng J Med 349: 2387-2398, 2003
8. Roehrborn CG, Kalan SA, Noble WD, et al.: The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. J Urol 175: 346, 2005
9. Steiner G, Gessl A, Kramer G, et al.: Phenotype and function of peripheral and prostatic lymphocytes in patients with benign prostatic hyperplasia. J Urol 151: 480, 1994
10. Ishigooka M, Hashimoto T, Hayami S, et al.: Clinical and retrospective evaluation of eviprostat: a non-hormonal and non-neuropharmacological agent for benign prostatic hyperplasia. Int Urol Nephrol 27: 61-66, 1995